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Limited diagnostic yield of endomyocardial 
biopsy after heart transplantation
Endomyocardial biopsy (EMB) is the method of choice 
to assess the potential rejection episodes in post-trans-
plant heart recipients [1]. Since it is an invasive procedure, 
it is associated with the risk of complications. Therefore, 
many attempts have been made to monitor the risk of po-
tential rejection in a non-invasive manner. Among them, 
IMAGE and the CARGO gene-expression profiling protocols 
ultimately proved to be promising. Nevertheless, in most 
of the heart transplant centers across the world, EMB re-
mained the gold standard to monitor rejection episodes. 
Moreover, the majority of the institutions developed local 
regimens of patient surveillance after heart transplan-
tation (HTx). They can be divided into two main groups, 
depending on the general assumptions. The first is fo-
cused on the high number of EMBs performed according 
to a routine schedule (routine surveillance EMB – rsEMB), 
which in theory enables the diagnosis and treatment of 
acute cellular rejection (ACR) episodes before the devel-
opment of clinical signs of rejection. The second concept 
focuses on clinical symptoms that are believed to trigger 
EMB, which is performed in case of ACR suspicion – clin-
ically driven EMB (cdEMB). Since the diagnostic yield of 
rsEMB is limited, which means that the majority of the re-
sults are unable to prove rejection, it has been postulated 
to decrease the number of routinely performed EMBs [2].
Possible short- and long-term 
complications of EMB – from experimental 
to routine practice
EMBs – were first performed by the Japanese cardiac 
surgeons Sakakibara and Konno in 1962, with the latter 
being considered the inventor of the method [3]. Like-
wise, EMB was introduced to clinical practice by Caves 
and colleagues in 1974 [4]. Interestingly, Japanese scien-
tists made a significant contribution to the development 
and improvement of this technique. Nevertheless, due 
to medical–legislative reasons the national transplanta-
tion program in Japan for many years stayed below the 
national demands and possibilities. It should be empha-
sized that EMB, although widely characterized in the lit-
erature as a relatively safe technique with only a few un-
favorable outcomes, may be associated with either acute 
or delayed complications – its frequency varies between 
3% and 6% [5, 6]. Right ventricle perforation with the 
subsequent pericardial tamponade (0.5–2.6%) pneumo-
thorax (1%), iatrogenic puncture of arteries (2%), nerve 
paresis (0.1%), hematomas (0.4%) and peripheral arterial 
to venous fistulas (0.1%) are to be enumerated among 
acute complications [6, 7]. Time-delayed complications 
consist of local bleeding (0.4%), mechanical impairment 
of tricuspid valve (25%) and pericardial effusion with de-
layed tamponade (3%) [5, 7, 8]. 
Technical aspects of EMB – now and then
Historically, EMB was performed percutaneously via 
the supraclavicular approach to either the right or the left 
subclavian vein. A  9-French (Fr) sheath was introduced 
using Seldinger’s technique; subsequently, a  dedicated 
curved 7-Fr catheter was placed in the proximity of the 
interventricular septum. Then, the 7 Fr bioptome was 
introduced through the sheath to obtain tissue speci-
mens for the histopathological assessment. Techniques 
currently used focus on safety-associated issues – ul-
trasound examination before acquiring vascular access, 
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flexible forceps with individually adapted curvatures, 
smaller sheaths to prevent vascular trauma, utilization of 
sheath-less techniques, etc. The approach above, includ-
ing simultaneous ultrasound-guided puncture of great 
veins (“in play mode”), is associated with a reduced num-
ber of serious local complications such as hematomas 
and/or bleeding.
Accessible clinical modalities to reduce 
the number of EMBs
Different institutions across the world use different 
biopsy regimens that are based on long-lasting experi-
ence in the field of transplantology. The number of rsEMBs 
may vary between two and fifteen, depending on the in-
stitutional experience. It is important to underline that 
the number of routinely performed EMBs must not be 
addressed without the connection between immunosup-
pressive treatment. It is believed that the induction with 
aggressive immunosuppression prevents the occurrence 
of rejection episodes, which have a huge impact on prog-
nosis. Treatment protocols currently used for induction 
therapy consist of a polyclonal anti-lymphocyte antibody 
or an anti-interleukin 2 (IL-2) monoclonal antibody. Rab-
bit anti-thymocyte globulin (rATG) is a T-cell-depleting an-
tibody therapy used either as induction of immunosup-
pression during the acute phase of the transplantation 
or in the treatment of the glucocorticoid-resistant acute 
rejection episodes [9]. Since rATG decreases the number 
lymphocytes, its use is associated with the potential in-
crease of life-threatening complications. Firstly, it is asso-
ciated with the allergy phenomenon; therefore, it should 
be administered with anti-allergic agents. Secondly, it is 
crucial to underline the raised patient’s vulnerability to 
infection, especially given at the initial phase after HTx. 
Among these, rapidly developing sepsis remains a major 
threat impairing in-hospital mortality. Last but not least, 
rATG is associated with the raised incidence of lymphop-
roliferative disorders. The alternatively used IL-2 (basilix-
imab) inhibits the proliferation of T-cells resulting from 
allograft antigen stimulation without a significant effect 
on the resting T-cells. Its different mechanism of action 
offers more selective immunosuppression. On the other 
hand, according to recent reports, it is associated with 
reduced 5-year survival after HTx as compared to rATG 
[10]. From the clinical point of view, the rATG activity is 
monitored via the CD3 count in the serum blood. In this 
phase the treatment brings to mind the phenomenon of 
the two-edged sword – on one side the patient may suf-
fer from acute rejection while on the other he might ex-
perience a serious, generalized infection. Since the rate 
of biopsy-proven rejections after rATG induction should 
by definition be less frequent, there exists a growing ten-
dency towards lowering the number of rsEMBs. Addition-
ally, this conception is supported by the growing experi-
ence that, during the regimen of the immunosuppression 
containing adequately performed rATG therapy, the EMBs 
could be uneventfully omitted, especially during the first 
4 weeks after HTx. It is noteworthy that some experi-
Zabrze’18 
EMB routine surveillance protocol 
How was created? 
Zabrze’18
EMB protocol safely reduces the number of routine surveillance EMBs by 20%. The omitted EMBs seem  
not to have a negative impact on outcomes
Induction therapy with rATG enables  
the safe reduction of EMBs during first  
12 months after HTx 
Zabrze EMB protocol consists of 10 EMBs 
performed during first 12 months  
after HTx 
1M–4 EMBs every week
1M–3 EMBs starting from 2nd week 
2M–2 EMBs every 2 weeks 
3M–1 EMB after 1 month 
6M–1 EMB every 3 months 
9M–1 EMB every 3 months
12M–1 EMB after 6 months 
1M–4 EMBs every week
2M–2 EMBs every 2 weeks 
3M–1 EMB after 1 month 
6M–1 EMB every 3 months 
9M–1 EMB every 3 months
12M–1 EMB after 3 months 
Figure 1. Zabrze’18 endomyocardial biopsy routine surveillance protocol
EMB – endomyocardial biopsy, rATG – rabbit anti-thymocyte globulin, 1–12M – one to twelve months, HTx – heart transplantation.
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enced centers limit the executed routine biopsies, in the 
first year after transplantation, to two performed in the 
third week and the twelfth month after the procedure. 
We predefined the group of heart recipients pre-
senting the highest potential to improve outcomes with 
the novel induction regimen. We focused on the immu-
nological status and comorbidities prior to HTx in order 
to perform an individually tailored immunosuppression 
consisting of rATG. Inclusion criteria would be: informed 
written consent, age 18–65 years and panel reactive an-
tibody score over ten percent. Exclusion criteria would 
be: bridge therapy with mechanical circulatory support 
prior to HTx, glomerular filtration rate less than 45 ml/
min/1.73 m2 and the absence of active infection.
Current implications for clinical practice
With the continuously growing number of potential 
HTx recipients, modern transplantation programs are 
changing their attitude towards difficult donor-recipient 
pairs. There is a rising acceptance of transplantation in 
older patients with many comorbidities and bridged with 
assist devices. Moreover, the advanced age of the donors, 
especially given in Europe, is responsible for many new 
challenges occurring in the early post-transplant period. 
These phenomena reflect the sociological changes of the 
population of many Central and Eastern European coun-
tries. Zabrze, being a leading heart and lung transplanta-
tion center in Poland, has performed 76 heart and 27 lung 
transplantations this year. This cutting-edge transplanta-
tion program forced the implementation of the necessary 
changes. Since, due to legislative reasons, the EMB pro-
cedure is reimbursed only if the patient stays overnight 
in the hospital, the raised number of HTxs performed will 
ultimately impact upon the organization of the specific 
services. Thus the implementation of the Zabrze’18 EMB 
protocol will help cover all of the diagnostic demands in 
the cohort of the patients after HTx. To see the general 
assumptions please refer to Figure 1 depicted below. 
Conclusions
The lack of routinely performed EMBs in the first 
week and nine months after HTx will decrease the total 
number of EMBs by 20% according to the EMB proto-
col currently used. This feasible option is accessible on 
the condition of intensive immunosuppression induction 
with rATG and extremely careful microbiological sensi-
tivity, including anti-bacterial and anti-viral prophylaxis, 
especially if given in the early post-transplant period. 
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